First-in-Man Use of the Tractus™ Crossing Support Catheter with its Jigsaw Technology™ Shaft

First-in-Man Use of the Tractus™ Crossing Support Catheter with its Jigsaw Technology™ Shaft




First-in-Man Use of the Tractus™ Crossing Support Catheter with its Jigsaw Technology™ Shaft

Crossing Technology Offers Catheter Labs

EATONTOWN, N.J.–(BUSINESS WIRE)–Tractus Vascular, LLC today announced the first-in-man use of the TractusTM Crossing Support Catheter (TractusTM CSC). The TractusTM CSC represents a highly novel approach to treating vascular disease.

Chronic total occlusion (CTO) remains one of the most challenging pathologies encountered by surgeons and interventionalists in performing endovascular interventions. Drs. John H. Rundback and Kevin Herman of American Endovascular & Amputation Prevention in West Orange, NJ both used the TractusTM CSC to treat several patients with challenging cases of critical limb ischemia including CTO’s. Dr. Rundback noted, “The Tractus catheter tracked like ice and performed exceptionally well; the cases were all extremely successful.”

The TractusTM CSC is US FDA 510(k) cleared with 0.014”, 0.018” and 0.035” guidewire compatibility and lengths of 90, 135, 155 and 170 cm. While most crossing support catheters are constructed with a braided sheath, Tractus offers their Jigsaw TechnologyTM laser cut stainless steel shaft consisting of a continuous helical cut pattern forming interlocking teeth. Distal “gusset cuts” offer a continuous stainless-steel tip which extends the attributes of this novel catheter shaft.

About Tractus Vascular, LLC

Tractus is dedicated to creating catheter products that excel in the treatment of challenging CTO’s and partial occlusions while matching the economies of today’s catheter lab. CTO’s in the arterial vasculature are characterized by heavy arteriosclerotic plaque burden resulting in complete, or near complete occlusion of a vessel. CTO’s in the venous vasculature, also known as chronic venous occlusion, is most common in the legs and is characterized by vein wall remodeling, collagenous fibrosis, and luminal reduction. Tractus intends to use its Jigsaw TechnologyTM to expand its product family of crossing devices especially where maximum buckling resistance, and therefore push force is needed. Tractus which is an ISO 13485 certified company has received and is the process of receiving several regulatory approvals. Tractus was created from incubator company Tinker Med, LLC.

Contacts

Janet Galtes, CEO

formerly known as Janet Burpee
Tractus Vascular, LLC

jburpee@tractusvascular.com
(732) 590-1470